Overview

• The Phase IIa GENESIS-IPF trial enrolled 71 patients across 22 sites in China who received placebo or varying doses of Rentosertib over 12 weeks.
• Patients in the highest dose cohort (60 mg once daily) experienced a mean forced vital capacity increase of 98.4 mL compared with a 20.3 mL decline in the placebo group.
• Treatment-emergent adverse events were generally mild to moderate and occurred at similar rates across cohorts, with serious events being rare and resolving after drug discontinuation.
• Biomarker analyses revealed dose-dependent reductions in fibrosis-associated proteins such as COL1A1, MMP10 and fibroblast activation protein alongside an increase in anti-inflammatory cytokine IL-10 in high-dose patients.
• Rentosertib was discovered using Insilico Medicine’s generative AI platform, cutting preclinical candidate nomination timelines to 12–18 months and showcasing AI’s role in accelerating drug discovery.